Introduction
============

Hematopoietic stem cell transplants (HSCT) is an effective therapy in the treatment of hematological malignancies such as leukemias and lymphomas ([@b1-mmr-19-03-1435]). The regimens required for transplant produce profound immune deficiency in the early period after transplantation ([@b2-mmr-19-03-1435]). Conditioning regimens include: Myeloablative (MAC) and reduced intensity conditioning (RIC). MACs include concomitant or single use of alkylating agents, such as cyclophosphamide (Cy) and busulfan (Bu), while RICs are mainly performed with fludarabine (Flu) or low doses of total body irradiation (TBI) ([@b3-mmr-19-03-1435],[@b4-mmr-19-03-1435]). Choice of conditioning depends on patient\'s age, underlying disease, relevant comorbidities and type of donor. These regimens are related to several risks such as infections, graft-vs.-host disease (GVHD) and post-transplant lymphoproliferative disorder (PTLD) ([@b5-mmr-19-03-1435]). GVHD occurs in approximately 40--90% of transplanted patients ([@b6-mmr-19-03-1435]). ATG seems to be effective in GVHD prophylaxis, and is related to reduced rates of relapses and infections in adults who undergo bone marrow (BM) or peripheral blood stem cells (PBSC) transplant ([@b7-mmr-19-03-1435]).

Rates of mortality after HSCT often reach up to 50.0% ([@b5-mmr-19-03-1435]). Some studies describe that intensive conditioning regimens are associated with reduction of tumor relapses, although it might simultaneously increase the transplant-related mortality rates, including the mortality of infections ([@b4-mmr-19-03-1435]).

Epstein-Barr virus (EBV) is a ubiquitous Human Herpes virus and infects 50--89% of children and remains latent, in memory B cells, of \~90% of adults ([@b8-mmr-19-03-1435]). Viral infections are known to be a major cause of morbidity and mortality in patients undergoing HSCT and Herpes virus are known to be among the most common viral infections in these patients ([@b5-mmr-19-03-1435]). The iatrogenic suppression of T-cell with the immunosuppression of the transplant regimens, allows the proliferation of infected B cells ([@b9-mmr-19-03-1435]). EBV is one of the most important viruses in transplanted patients, and monitoring of EBV DNA in peripheral blood is routinely performed in several transplant centers, since these patients have a higher-risk of developing complications ([@b9-mmr-19-03-1435]--[@b13-mmr-19-03-1435]).

This study aims to analyze the impact of the different characteristics of allogeneic-HSCT (aHSCT) patients and correlate with the development of EBV infection.

Materials and methods
=====================

### Type of study and study participant

A prospective follow-up study was performed with 40 consecutive patients who underwent aHSCT at the *Bone Marrow Transplant Service* of *Portuguese Oncology Institute of Porto* (IPO Porto; Porto, Portugal) between January and December of 2015. Cases were selected randomly from the cohort of patients undergoing aHSCT. The study was approved by the local Ethical Committee and did not interfere with the routine procedures decided by clinicians. Clinical data was collected from individual clinical records and stored in a database with unique codification.

### Sample processing

EBV detection is not routinely requested for all HSCT patients in our institution (only for high-risk), and therefore we have used samples collected during routine procedures for patients monitoring selected at 6 different times: D+30, +60, +90, +120, +150 and +180 days after transplant. Samples were collected in EDTA-containing tubes and stored prior to processing.

Sample processing was performed at the Virology Service of IPO Porto. DNA was extracted by *MagNA Pure Compact Nucleic Acid Isolation kit I* (Roche, Germany). DNA/RNA quality was assessed by measuring the absorbance at 260/280 nm with NanoDrop 1000 Spectrophotometer v3.7 (Thermo Fischer Scientific, Inc., Wilmington, MA, USA).

### EBV detection

EBV detection was performed with a real-time PCR protocol targeting EBV polymerase gene (EBV POL) as previously reported ([@b14-mmr-19-03-1435]). Amplification was performed with the ABI PRISM 7300 Sequencer Detection System (Applied Biosystems, Foster City, CA, USA) and results were obtained by measuring the geometric increase of probe fluorescence during amplification and samples were considered positive when the exponential curve exceeded the cycle threshold line. All amplifications used positive and negative controls: As negative control, we used double distilled water in replacement of template DNA; and as positive control we have used samples from the External Quality Control panel for EBV used at the Virology Service. Results were independently analyzed by two of the authors and 10% of all samples were randomly selected and re-submitted to amplification to confirm the results.

### Statistical analysis

Statistical analysis was performed with IBM^®^ SPSS Statistics 20 software (IBM Corp., Armonk, NY, USA) for Mac. Chi-square or Fisher\'s exact test with a 5% significance level were used to estimate odds ratio (OR) and the corresponding 95% confidence intervals (CIs) as a measure of association between the categorical variables and the risk of EBV infection. Cox proportional hazard models were used to assess the risk factors associated EBV infection. Kaplan-Meier with log-Rank test was used to calculate the association between EBV infection and post-transplant survival (OS).

Results
=======

### Clinical characteristics

This study included 40 patients, 27 males (67.5%) and 13 females (32.5%), with ages between 1 and 63 years-old (mean 32.2±1.5, median 35 years old) who underwent aHSCT at our institution between January and December of 2015.

[Table I](#tI-mmr-19-03-1435){ref-type="table"} demonstrates the characteristics of all patients. Briefly, patients were submitted to aHSCT due to different hematological malignancies, including aplastic anemia (n=3), acute leukemia (n=23), chronic leukemia (n=2), non-Hodgkin lymphoma (n=1), multiple myeloma (n=1), myelodysplastic/myeloproliferative syndrome (n=7) and others, including primary immunodeficiency, myelofibrosis and severe combined immunodeficiency (n=3). Off the 40 patients submitted to aHSCT only one was being transplanted for the second time. When evaluating the donor-receptor relation, 21 patients had unrelated donors (52.5%) and the remaining 19 had related donors (47.5%). Regarding the HLA-match, only one patient received a graft from a HLA-mismatched donor. The source of cells for transplant was mainly from peripheral blood (82.0%), while the remaining were from BM (13.0%) and umbilical cord blood (5.0%). MAC conditioning was used in 24 (60.0%) of our patients, with Bu and cyclophosphamide, as well as ATG which was used in 14 of these patients. Reduced intensity regimens were used in 16 patients with 6 of them receiving ATG. Patients with unrelated donors, except in one case, received ATG as part of GVHD prophylaxis. Prophylaxis for GVHD was performed for all patients (data not available for 2 patients). Acute GVHD (aGVHD) was observed in 21 patients, all of them with grade 2 or higher; while chronic GVHD (cGVHD) was present in 5 patients, 4 with evolution from aGVHD and only one with *de novo* cGVHD.

EBV and CMV serological status was described as: IgM positive and IgG negative/positive (active infection); IgM negative and IgG positive (past-infection); and IgM negative and IgG negative (susceptible). In our study, we found 3 patients were susceptible for EBV-primary infection, 1 patient had an active EBV-infection and 7 patients were susceptible of CMV-primary infection (data not shown).

### EBV infection

The overall data reveal that 70% of patients were at least once positive during the follow-up period. Regarding the specific times of sample collection in our study, results showed the presence of EBV in 10/40 (25%) at D+30, 18/38 (47%) at D+60, 13/34 (38%) at D+90, 9/29 (31%) at D+120, 10/22 (45%) at D+150, and 7/12 (58%) at D+180 ([Fig. 1](#f1-mmr-19-03-1435){ref-type="fig"}).

The analysis of EBV DNA positivity (at least once positive) and its association with clinicopathological characteristics of patients is shown in [Table II](#tII-mmr-19-03-1435){ref-type="table"}. The analysis according to sex seem to show that post-transplant EBV infection is more frequent in females (OR=8.33, P=0.033). Despite not statistically significant, we have found that EBV infection is more frequent in patients with unrelated donors (OR=3.12, P=0.112), engrafted with PBSC (OR=2.00, P=0.414), submitted to MAC conditioning regimen (OR=2.96, P=0.121), using ATG in the conditioning regimen (OR=2.91, P=0.135), and that developed aGVHD (OR=3.09, P=0.112). Despite we observe an increased prevalence of EBV in older patients, there was no statistically significant association regarding age (child vs. adults, or median age) (P\>0.050). EBV serostatus prior to transplant does not seem to be related with the development of infection during the post-transplant period (data not shown).

The analysis of EBV infection at the different times during the follow-up period revealed different associations with clinicopathological data, despite not all with statistical significance. At D+60, EBV infection was associated with transplants from unrelated donors (OR=3.9, P=0.058), with MAC conditioning (OR=4.3, P=0.052) and use of ATG (OR=3.6, P=0.099), although, with no statistical significance; at D+90, development of GVHD was related a higher risk of infection (OR=6.7, P=0.032); and finally, at D+150, EBV infection was associated with unrelated donors (OR=8.0, P=0.043), use of ATG (OR=12.0, P=0.030) and development of GVHD (OR=5.6, P=0.099). There was no significant association between age and EBV infection in different times (data not shown). The Cox regression analysis considering patients sex, type of donor, conditioning regimen, use of ATG and development of aGVHD, revealed an association of unrelated donor with EBV infection at D+150 (HR=8.8, P=0.030).

### Follow-up

None of these patients had clinical suspicion or development PTLD during follow-up. Of the 40 patients included in this study, 16 patients have deceased, 6 are alive with evidence of disease and 18 are alive without evidence of disease. Cumulative survival was evaluated by performing a Kaplan-Meier plot and estimated survival time was approximately 476±58.7 days (data not shown).

Analysis of EBV-infection impact on overall survival (OS) is shown in [Fig. 2](#f2-mmr-19-03-1435){ref-type="fig"}. The impact of EBV infectionon OS, in different times, is shown in [Fig. 3](#f3-mmr-19-03-1435){ref-type="fig"}. Results suggest that EBV positivity at D+90 days and D+180 may be associated with increased mortality (P=0.095, 303.3 vs. 593.2 days and P=0.097, 367.0 vs. 679.5, respectively).

Discussion
==========

aHSCT is an option for the treatment of hematological malignancies and these patients are submitted to pre-transplant treatments that reduce significantly the immune system to avoid rejection of the graft ([@b15-mmr-19-03-1435]). This immunosuppression is associated with the occurrence of different events in the post-transplant period, such as development of GVHD, infections and PTLDs ([@b16-mmr-19-03-1435]). Viral infections are a major concern in the subset of aHSCT, and while CMV infection has been consistently associated with a significant morbidity/mortality increase ([@b17-mmr-19-03-1435]--[@b19-mmr-19-03-1435]), EBV infection has been underestimated in these patients since only a minority will suffer from EBV-associated complications, such as PTLD ([@b11-mmr-19-03-1435],[@b13-mmr-19-03-1435],[@b20-mmr-19-03-1435]).

The incidence of EBV DNAemia varies within transplant centers, ranging from 0.1 to 63% ([@b11-mmr-19-03-1435],[@b21-mmr-19-03-1435],[@b22-mmr-19-03-1435]). In our study, we verified that 70.0% of our patients were positive for EBV, at least once during the follow-up period, nevertheless the prevalence of EBV-positive patients at a specific time ranged from 25--58%. Dumas *et al*, monitored EBV viral load at least once a week for 3 months and verified that EBV DNAemia occurred in approximately 14.0% of patients, which is significant lower than what we describe ([@b23-mmr-19-03-1435]). Hence, these results show that there are significant differences amongst transplant centers that may be explored considering the individual characteristics of patients.

Literature refers that EBV infection is most common within the first 100 days post-transplant, in high-risk patients ([@b24-mmr-19-03-1435],[@b25-mmr-19-03-1435]). In our study, we describe that EBV infection varied throughout the follow-up period, with a mean of 65.6±39.6 days (range, 27--183). According to the guidelines for diagnosis and monitoring of EBV DNAemia, the monitoring should be performed by quantitative PCR and monitorization must start at the first month post-transplant, and should be performed at least during 4 months after transplantation, with a weekly frequency ([@b11-mmr-19-03-1435],[@b12-mmr-19-03-1435]). Despite this, many authors discuss the cost-effectiveness of EBV monitoring once-a-week and therefore many studies are required to show what would be the best time and interval of monitoring. Moreover, EBV viral load has been having different input data since the cutoff viral loads for treatment are variable and the development of international standardization of EBV viral load management is yet to be defined ([@b12-mmr-19-03-1435],[@b13-mmr-19-03-1435],[@b26-mmr-19-03-1435]). Gulley and Tang, affirm that routine monitoring of EBV infection is viable in PTLD prevention, although further studies must be done to correlate specific viral loads in the identification of high-risk patients ([@b27-mmr-19-03-1435]). As defined by published guidelines, rituximab therapy is used prophylactically before or shortly after transplant to reduce the risk of EBV DNAemia and PTLD development in high-risk patients, such as patients with EBV-seropositive donors ([@b11-mmr-19-03-1435]). In these cases, viral load is also informative, when there is a withdrawal of immunosuppression, and rituximab administration, to verify if the treatment is being successful ([@b27-mmr-19-03-1435]).

The identification of high-risk patients for EBV infection is crucial for the correct clinical approach of EBV-associated morbidity/mortality in aHSCT patients. Accessing variables associated with transplant, and complications associated with treatment, such as PTLD, include patients into two groups: High-risk and low-risk. High risk patients have pre-transplant risk factor such as T-cell depletion, EBV serology donor/recipient mismatched, cord blood transplantation, HLA mismatch, Splenectomy and second HSCT; and post-transplant risk factors as severe acute or cGVHD and high or rising EBV DNAemia ([@b11-mmr-19-03-1435],[@b13-mmr-19-03-1435],[@b25-mmr-19-03-1435],[@b28-mmr-19-03-1435]).

Our data showed that patients with unrelated and/or mismatched donors were more prone to develop an EBV infection post-transplant, and that using peripheral blood as source of stem cells adds a higher risk for EBV infection. Studies report EBV infections of 8.8% in MAC conditionings and 35.0% in RICs ([@b29-mmr-19-03-1435]), 54.0% in T-cell depletion ([@b30-mmr-19-03-1435]) and 65.0% in T-cell depletion concomitant with ATG use ([@b22-mmr-19-03-1435]). Xuan *et al* showed that the use of ATG, HLA-mismatched, unrelated donor and acute aGVHD were identified as risk factors for EBV infection ([@b4-mmr-19-03-1435]). These findings are according those reporting that intensified conditioning increase the incidence of EBV viremia and disease ([@b4-mmr-19-03-1435]). In our study, myeloablation conditioning and use of ATG demonstrated a 3-times higher risk of developing EBV infection. ATG has been widely used to decrease the incidence of GVHD ([@b31-mmr-19-03-1435]), however, because of T-cell depletion, ATG is also associated with relapse ([@b32-mmr-19-03-1435]). The optimal dose of ATG depends on transplant characteristics, such as type of donor, and may range from 2.5 to 30 mg/kg ([@b33-mmr-19-03-1435]). ATG has beneficial effects in preventing GVHD, although it delays immune reconstitution, promoting an increased risk of EBV reactivation, and potentially EBV-associated lymphoproliferative disease ([@b34-mmr-19-03-1435]). Literature shows that higher doses of ATG seem to be related with PTLD development ([@b35-mmr-19-03-1435]). Indeed, at our institution, no more than 10 mg/kg is used, and this may have contributed for the fact that no PTLD was observed in this cohort. When addressing the development of GVHD, we observed that patients who developed aGVHD, had 3-times increased association with EBV infection. Furthermore, we noticed that all patients with cGVHD, were positive for EBV at least once in the post-transplant follow-up. As described previously by Janeczko *et al*, GVHD is related to delayed immune reconstitution, favoring infections in the early period post-transplant. Moreover, viral infections are also associated with delayed immune response and appear to be linked to the degree of immunosuppression ([@b36-mmr-19-03-1435]).

Review of EBV infection on different periods post-transplant revealed that unrelated donor, myeloablation and the use of ATG seem to be risk factors for EBV infection occurrence at D+60; while GVHD is connected to EBV infection at D+90; and ATG, unrelated donor and GVHD are related to EBV infection at day D+150. These results seem to corroborate the literature regarding the identification of high-risk markers for EBV infection. Furthermore, our study reports that EBV positivity at D+90 days and D+180 might be associated with increased mortality (P=0.095, 303.3 vs. 593.2 days and P=0.097, 367.0 vs. 679.5, respectively). We acknowledge that EBV infection is not, by itself, responsible for higher mortality rates, therefore further studies should be performed with more patients.

EBV infection is still a major concern in the subset of HSCT and these results showed that EBV routine monitoring is useful in high-risk patients during the first months after transplantation. In a previous study, the authors accessed the importance of EBV monitoring in patients submitted to aHSCT, regarding the development of PTLD ([@b13-mmr-19-03-1435]). Although no patients of this study developed PTLD, it is still important performing EBV monitoring when several risk factors, are present. The implementation of guidelines and standardization of EBV monitorization in HSCT patients will contribute for the cost-effectiveness of this monitorization reducing unnecessary morbidity/mortality associated with EBV-infection.
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###### 

Clinical characteristics of patients.

  Characteristics                                 Number (%)
  ----------------------------------------------- --------------
  Age, median (range) years old                   32.2 (1--63)
  Sex, n (%)                                      
    Male                                          27 (67.5)
    Female                                        13 (32.5)
  Underlying disease, n (%)                       
    Aplastic anemia                               3 (7.5)
    Acute leucemia                                23 (57.5)
    Chronic leucemia                              2 (5.0)
    Non-Hodgkin lymphoma                          1 (2.5)
    Multiple myeloma                              1 (2.5)
    Myelodysplastic/myeloproliferative syndrome   7 (17.5)
    Others                                        3 (7.5)
  Conditioning regimen, n (%)                     
    BuCy                                          4 (10.0)
    BuCy2                                         20 (50.0)
    Cy                                            1 (2.5)
    FluBu                                         10 (25.0)
    FluCy                                         3 (7.5)
    FluMelf                                       1 (2.5)
  ATG, n (%)                                      
    Yes                                           20 (50.0)
    No                                            20 (50.0)
  Type of donor, n (%)                            
    Related                                       19 (47.5)
    Mismatched/unrelated                          21 (52.5)
  Source of cells, n (%)                          
    PBSC                                          33 (82.5)
    BM                                            5 (12.5)
    UCB                                           2 (5.0)

Bu, busulfan; Cy, cyclophosphamide; Flu, fludarabine; Melf, Melphalan; ATG, anti-thymocyte globulin; PBSC, peripheral blood stem cells; BM, bone marrow; UCB, umbilical cord blood.

###### 

Analysis of EBV infection among allogeneic hematological stem cell transplant recipients.

  Variable                            EBV infection n (%)   P-value   OR (95% CI)
  ----------------------------------- --------------------- --------- -------------------
  Sex                                                                 
    Male (n=27)                       16 (59.3)             0.033     8.33 (0.93--100)
    Female (n=13)                     12 (92.3)                       
  Stem cell source                                                    
    Cord blood or bone marrow (n=7)   4 (57.1)              0.414     2.00 (0.37--11.1)
    Peripheral blood (n=33)           24 (72.7)                       
  Conditioning regimen                                                
    Reduced intensity (n=16)          9 (56.3)              0.121     2.96 (0.73--11.9)
    Myeloablative (n=24)              19 (79.2)                       
  ATG                                                                 
    With (n=19)                       11 (57.9)             0.135     2.91 (0.70--12.1)
    Without (n=20)                    16 (80.0)                       
  Donor                                                               
    Related (n=19)                    11 (57.9)             0.112     3.12 (0.75--12.5)
    Unrelated (n=21)                  17 (81.0)                       
  Acute GVHD                                                          
    Absent (n=19)                     11 (57.9)             0.170     3.09 (0.75--12.8)
    Present (n=21)                    17 (81.0)                       
  Age                                                                 
    \<20 years old (n=14)             8 (57.1)              0.173     2.50 (0.62--10.1)
    ≥20 years old (n=26)              20 (76.9)                       
    \<35 years old (n=20)             13 (65.0)             0.366     1.61 (0.41--6.34)
    ≥35 years old (n=20)              15 (75.0)                       

ATG, anti-thymocyte globulin; GVHD, graft-vs.-host disease; CI, confidence interval; OR, odds ratio; EBV, Epstein-Barr virus.
